TRPM8 Ion Channels Differentially Modulate Proliferation and Cell Cycle Distribution of Normal and Cancer Prostate Cells by Valero, María Llanos et al.
TRPM8 Ion Channels Differentially Modulate
Proliferation and Cell Cycle Distribution of Normal and
Cancer Prostate Cells
Marı´a Ll. Valero1,2¤, Fernanda Mello de Queiroz1, Walter Stu¨hmer1,3, Fe´lix Viana2, Luis A. Pardo1*
1Department of Molecular Biology of Neuronal Signals, Max-Planck Institute of Experimental Medicine, Go¨ttingen, Germany, 2 Instituto de Neurociencias de Alicante,
Universidad Miguel Herna´ndez-CSIC, Alicante, Spain, 3DFG Research Center for Molecular Physiology of the Brain (CMPB), Go¨ttingen, Germany
Abstract
Overexpression of the cation-permeable channel TRPM8 in prostate cancers might represent a novel opportunity for their
treatment. Inhibitors of TRPM8 reduce the growth of prostate cancer cells. We have used two recently described and highly
specific blockers, AMTB and JNJ41876666, and RNAi to determine the relevance of TRPM8 expression in the proliferation of
non-tumor and tumor cells. Inhibition of the expression or function of the channel reduces proliferation rates and
proliferative fraction in all tumor cells tested, but not of non-tumor prostate cells. We observed no consistent acceleration of
growth after stimulation of the channel with menthol or icilin, indicating that basal TRPM8 expression is enough to sustain
growth of prostate cancer cells.
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Introduction
TRPM8 is a calcium-permeable, non-selective cation channel of
the transient receptor potential superfamily [1], required for the
transduction of moderate cold temperatures [2,3]. The presence of
TRPM8 in cold-responsive small-diameter neurons in dorsal root
ganglia and trigeminal ganglia and the phenotype detected in
TRPM82/2 knockout mice supports a role of TRPM8 in
thermosensation and nociception [4–6]. TRPM8 channels have
been cloned from species in different genera, from amphibians to
humans [7]. Human TRPM8 was initially identified during a
screen for up-regulated genes in prostate cancer (and therefore
termed trp-p8 [8] but later detected in other tumor types [9,10].
Among normal tissues the expression of the channel is very
restricted to a subpopulation of primary sensory neurons [2,3], but
it is also present in the male reproductive system in significant
amounts [2,3,8,9,11,12].
Activation of endogenous (i.e. neuronal) or recombinant
TRPM8 channels gives rise to a signature current characterized
by extreme outward rectification and voltage-dependent gating
[13–15]. TRPM8 channels can be activated by specific and
selective agonists, either natural (such as eucalyptol and menthol)
or synthetic compounds like the super cooling agent icilin, which is
so far the most potent agonist of TRPM8 [2,3,16–19]. Other
agonists (linalool, geraniol, among others) were identified by
screening menthol derivatives or odorant compounds. In partic-
ular, geraniol might be a physiological activator of TRPM8
because it is an intermediate during cholesterol synthesis and it
induces proliferation in prostate epithelium. All known TRPM8
agonists induce a cooling effect, reinforcing the concept of a role of
TRPM8 in cold perception [20].
TRPM8 mRNA has been detected in malignant cells, and this
has been extensively studied in prostate cancer. TRPM8 mRNA
was highly overexpressed in well-differentiated early prostate
tumors. In a typical model for androgen-dependent prostate
cancer (LNCaP cells; epithelial apical cells with a secretory
phenotype) expression is detected at both the plasma membrane
and the endoplasmic reticulum, where it could act as a Ca2+
release channel [18,19,21–23]. Plasma membrane TRPM8 might
exert a protective effect, since activation of TRPM8 by PSA
(prostate specific antigen) reduced cell motility in PC3 cells [24].
TRPM8 might be a useful marker for prostate cancer outcome,
since loss of TRPM8 expression appears to be associated to
transition to androgen independence and poor prognosis
[19,21,25]. This might reflect the effect of androgens on TRPM8
expression, since the gene displays ten putative androgen
responsive elements [18]. Abnormal levels of TRPM8 mRNA
can also be indicative of metastatic disease [26].
Canonical TRPM8 channel function can be blocked by urea
compounds (see below), which are also known to inhibit TRPV1
[17,25,27]. This limits the use of such blockers in the study of the
role of TRPM8 in prostate cancer because the cells express also
TRPV1 [28]. At present, the only feasible way to specifically
dissect the role of the channel in prostate cancer is the use of
siRNA. RNA interference can produce an effective and specific
knock down of a particular gene in vivo and in vitro [29,30].
In this study we examined the effects that TRPM8 silencing has
on cell survival and cell proliferation of three human prostate cells
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lines, LNCaP, PC3 and DU145. LNCaP is strongly androgen-
dependent [19] while DU145 is androgen-independent [31] and
PC3 would represent an intermediate status [32]. We also studied
the behavior in this respect of a non-tumoral (SV40 immortalized)
prostate cell line, PNT1A [33]. Inhibition of the expression or
function of the channel reduced proliferation rates and prolifer-
ative fraction in all tumor cells tested, but not of non-tumor
prostate cells.
Materials and Methods
Cell Culture
Prostate-derived cell lines PNT1A (ECACC 95012614), LNCaP
(DSMZ ACC 256), PC3 (DSMZ ACC 465) and DU145 (DSMZ
ACC 261) were obtained from DSMZ (Braunschweig, Germany)
or ECACC (Salisbury, UK). Each line was propagated and
maintained according to the instructions of the corresponding
provider. Identity of tumor cell lines was confirmed through
expression of specific markers (PC3 AR2, ERa+, ERb+, PSA2,
DD32; DU145 AR2, ERa2, ERb+, PSA2, DD32; LNCaP
AR+, ERa2, ERb+, PSA+, DD3+; Paul Thelen, Department of
Urology, University Hospital Go¨ttingen).
siRNA Transfections
Transfection with siRNAs (25 nM) was performed using either
Lipofectamine 2000 or Lipofectamine RNAiMAX reagents in
OptiMEM medium (Invitrogen GmbH, Karlsruhe, Germany) 24
hours after plating. Four different siRNAs were designed to target
hTRPM8 channel using the HiPerformance siRNA Design
Algorithm (Qiagen). The following hTRPM8 (NM_024080)
sequences were used: TRPM8.1, tcgaatgttctcacctattaa; TRPM8.2,
aaggttagattccaataaata; TRPM8.3, cagaatgttatcatactacat and
TRPM8.4, ccgggacgagatggacataga.
All siRNAs were synthesized by Qiagen (Hilden, Germany),
except the commercial Negative Control #1 and the human
GAPDH siRNA (Ambion, Darmstadt, Germany), which we used
as negative and positive controls, respectively. The cells were
incubated with the siRNA and the transfection reagent for 6 h and
harvested for the experiments just after the end of transfection.
Additionally, cells treated only with OptiMEM and the corre-
sponding transfection reagent were included as controls.
qPCR
Total RNA obtained from cultures using RNeasy mini kit
(Qiagen, Hilden, Germany) was reverse transcribed (SuperScript,
Invitrogen, Karlsruhe, Germany) with oligo-dT and gene specific
primers for hTRPM8 (59-cttgggcaaaacacacaatg-39). Real-time
PCR was performed on the template using the TaqMan system
in an AbiPrism 7700 Sequence Detector (Applied Biosystems,
Foster City, CA) or a LightCycler 480 (Roche, Mannheim,
Germany). The following fragments were amplified: nt 2910–3058
from sequence NM_024080.4 was detected with the hTRPM8
probe (59-FAM-tcgccatgtttggctacacggtgggcacc-TAMRA-39) and nt
1632–1732 from sequence NM_003234 was detected with the
hTFR probe (59-JOE-tgaatggctagagggatacctttcgtccc-(6-TAMRA)-
39). The human transferrin receptor was used as a control template
for RNA integrity and PCR performance. Relative quantification
was performed using the REST software (Relative Expression
Software Tool; [34,35]).
Flow Cytometry
siRNA: After treatment with siRNA, cells were plated in 6-well
plates and were incubated for 24–120 h before measurements.
Cells were trypsinized, washed twice with PBS and subsequently
kept on ice. For cell cycle measurements, the cells were incubated
with 50 mg/ml propidium iodide (PI), 0.3% saponine and 100 U/
ml RNase. For viability measurements, non-viable cells were
detected by staining with 10 mg/ml PI in PBS. Samples were
analyzed on a BD FACSAria flow cytometer (Becton Dickinson,
Heidelberg, Germany). Propidium iodide was excited at 488 nm,
and fluorescence was collected using a 595 nm dichroic mirror
and 610/20 nm band-pass filter (for cell cycle) or 655 nm dichroic
mirror and 695/40 nm band-pass filter (for viability). Gates for
viable cells were established by forward- and side scatter and cell
cycle phases were determined using the FlowJo software (Tree Star
Inc., Ashland, USA). Alternatively, the percentage of viable cells
was directly determined by PI exclusion.
For experiments in the presence of menthol and icilin, cells were
plated in 6-well plates and incubated for 24–168 h with 125–
300 mM menthol or 10 mM icilin before measurements. Cells were
trypsinized, and washed twice with PBS. Samples were treated and
analyzed for cell cycle and viability measurements as described
before.
Calcium Imaging
The calcium imaging experiments were conducted with the
fluorescent indicator Fura-2. Prior to each experiment, the cells
were incubated with 5 mM acetoxymethylester form of Fura-2
(Fura-2AM; Invitrogen) for 45 min at 37uC. After this, 250 mM of
sulfinpyrazone was added for another 20 min in order to block the
anion transporter that impairs the loading with Fura-2AM in the
cancer cells lines. Fluorescence measurements were made in a
Leica (Nussloch, Germany) DM IRE2 inverted microscope
equipped with a 12-bit cooled CCD camera (Imago QE Sensicam;
TILL Photonics, Graefelfing Germany). Fura2 was excited at 340
and 380 nm with a Polychrome IV monochromator (TILL
Photonics) and the emitted fluorescence was filtered through a
510 nm long-pass filter. Calibrated ratios were displayed on line at
0.5 Hz using TILL Vision software version 4.01 (TILL Photonics).
The calcium imaging experiments were performed simultaneously
with temperature recordings. The bath solution, referred to as
‘control solution’, contained (mM): NaCl 140, KCl 3, CaCl2 2.4,
MgCl2 1.3, Hepes 10 and glucose 10, and was adjusted to pH 7.4
with NaOH.
Proliferation Assays
Proliferation was estimated based on the ability of metabolically
active cells to reduce tetrazolium salts to colored formazan (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT;
Sigma-Aldrich). Cells were trypsinized and plated in flat bottom
96-well plates at densities ranging from 2000 to 5000 cells/well
depending on the cell line examined. To determine the metabolic
activity, 10 ml of MTT reagent were added to each well and
incubated for 4 h. The absorbance of the produced formazan was
determined in a Victor2 plate reader (Wallac) using 570 nm and
630 nm excitation filters. For experiments with menthol, the
medium was renewed every 48 h both in the test and control wells.
Wound Healing Assay
Cells were first cultured to confluence (.90%) in 6-well dishes.
A small area was then disrupted by scratching the monolayer with
a 1000 ml plastic pipette tip. Thereafter, the cells were cultured for
12, 24 or 48 h under different experimental conditions: low serum
or either vehicle or drug-containing medium. Cells were inspected
microscopically over time. The remaining wound area was
calculated using CorelDraw software and the migration distance
of the cells was estimated based on that calculation.
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Drugs
4-(3-Chloro-pyridin-2-yl)-piperazine-1-carboxylic acid (4-tert-
butyl-phenyl)-amide (BCTC) was a generous gift from Gru¨nenthal
AG (Aachen, Germany). [L-arginyl]-[N-[2,4-dichlorophenethyl]-
glycyl]-N-(2,4-dichlorophenethyl)glycinamide (DD01050; (H-Arg-
15-15 C in [36]), was a gift from Dr. A. Ferrer-Montiel
(Universidad Miguel Herna´ndez, Spain). AMTB (N-(3-aminopro-
pyl)-2-[(3-methylphenyl)methoxy]-N-(2-thienylmethyl)-benzamide
hydrochloride (1:1) hyclate) a novel, highly selective TRPM8
antagonist was a generous gift of Dr. Stuart Bevan (King’s College,
London). JNJ41876666 (compound 5 in reference [37]; 3-[7-
Trifluoromethyl-5-(2-trifluoromethyl-phenyl)-1H-benzimidazol-2-
yl]-1-oxa-2-aza-spiro[4.5]dec-2-ene Hydrochloride,), a potent
TRPM8 antagonist, was a generous gift of Janssen Research &
Development, LLC (Spring House, PA). Fig. 1 shows the chemical
structures of the drugs used.
Statistical Analysis
Data are presented as mean 6 S.E.M. obtained from at least
three independent experiments. Statistical significance was eval-
uated by Student’s t test. P values are indicated in the figures by
asterisks near the corresponding column or symbol. * p,0.05; **
p,0.01; *** p,0.005.
Results
Detection of TRPM8 Expression in the Prostate and
Prostatic Cell Lines
TRPM8 expression is most abundant in nervous tissue and the
male reproductive system. Previous studies described the overex-
pression of TRPM8 in prostate tumors and cell lines derived from
prostate cancer, specifically LNCaP [8]. Other cell lines were
found negative in those reports. More recently, PC3 cells were
reported weakly positive by western blot [21]. We set to determine
expression levels of TRPM8 in the prostate cancer cells LNCaP,
PC3 and DU145 and the non-tumoral cell line PNT1A by
different approaches to expand and complement results reported
before [38].
First, TRPM8 mRNA content was determined by reverse-
transcription real-time PCR (qRT-PCR) using TaqMan probes in
normal human brain, prostate, and cell lines LNCaP, PC3,
DU145 (derived from tumors) and PNT1A (immortalized non-
transformed prostatic cell line). RNA integrity and reverse
transcription were controlled by using the human transferrin
receptor as reference for normalization. mRNA for TRPM8 was
detected in brain and prostate, with maximum levels in the healthy
prostate (not shown). The message was also detected in all human
cell lines tested, LNCaP, PC3, DU145 and PNT1A. As reported
Figure 1. Chemical structure of the drugs with TRPM8 antagonist activity used in this study.
doi:10.1371/journal.pone.0051825.g001
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previously, levels in the non-tumoral line PNTA1 were signifi-
cantly lower than in the cancer cell lines. The relative amount of
TRPM8 message was DU145<LNCaP.PC3.PNT1A (Fig. 2A).
From these results, we conclude that TRPM8 is expressed in all
prostatic cell lines tested. Furthermore, the protein appears to form
functional channels. In our hands, DU145 (Fig. 2B, C), LNCaP
and PC3 (data not shown) cells show an increase in intracellular
Ca2+ levels upon stimulation by menthol (500 mM) and moderate
cold (decrease in temperature from 36uC to 18uC), compatible
with the functional expression of TRPM8. Cold-evoked responses
in DU145 cells were strongly reduced by siRNA directed against
TRPM8 (Fig. 2D–F).
Effect of TRPM8 Blockers on the Proliferation of Prostate
Cancer Cell Lines
The experiments described so far support the notion that
TRPM8 expression occurs both in normal prostate and tumor
cells. The question remains, however, whether inhibition of
TRPM8 has similar effects in all cell types. Our main goal was to
test whether TRPM8 activity is a general requirement for the
proliferation of different prostate cancer cell lines. To test this, we
used pharmacological TRPM8 blockers [39] and siRNA technol-
ogy.
Blockers used (Fig. 1) were clotrimazole (EC50 200 nM) [40];
BCTC, a blocking agent of TRPV1 channels [41] and of mouse,
rat and human TRPM8 channels (with EC50 of approximately
0.6–1 mM) [13,17,27,42]; thio-BCTC, a less active (EC50 3.5 mM)
analog of BCTC; and DD01050, a novel TRPV1 channel blocker
which also blocks TRPM8 in neurons and HEK293 cells (EC50
approximately 1 mM) [38]. Proliferation was determined using
MTT assays (Fig. 3) and the effect of these drugs and a more
selective TRPM8 antagonist (see below) on the cell cycle
distribution and cell viability were determined by flow cytometry
(Fig. 4).
Clotrimazole is a well-established inhibitor of cancer cell
proliferation probably through multiple targets, including the
intermediate conductance calcium-activated K+ channels [43]. At
the concentration used (10 mM), clotrimazole inhibited the
proliferation of all tumor cell lines by 60 to 80% after five days,
but did not affect the growth of PNT1A cells (Fig. 3). BCTC at
10 mM showed a similar behavior to clotrimazole, since it strongly
reduced the proliferation of all cell lines (50–70%) but PNT1A.
The effects of BCTC appear to occur, at least in part (see below),
through its action on TRPM8, since thio-BCTC was clearly less
efficacious in all lines tested. Somewhat surprisingly, DD01050
(10 mM) induced a significant inhibition only in PC3 cells to a level
comparable to other inhibitors, but it did not show any significant
inhibition in any other cell line (Fig. 3).
The inhibition of proliferation correlated well with the
proliferative fraction which was measured as percentage of cells
in S/G2/M phases of the cell cycle. As shown in Fig. 4, the
relative potency of each blocker is also reflected in the decrease in
proliferative fraction induced. None of the drugs tested changed
the proliferative fraction of PNT1A cells. On the other hand, both
clotrimazole and BCTC (both at 10 mM), decreased the cells in S/
Figure 2. Expression and functional analysis of TRPM8 in prostate cancer cells. A. mRNA abundance was determined by real time PCR on
cDNA derived from RNA from the indicated source. The human transferrin receptor was used as reference housekeeping gene. RNA abundance is
expressed as normalized values over PNT1A. Asterisks indicate statistical significance with respect to PNT1A. B–C. DU145 cells respond to cold and
menthol. B. Transmitted (left) and pseudocolor ratiometric [Ca2+]i images showing an example of the response of DU145 cells to cold (18uC) and
menthol 500 mM. C. [Ca2+]i responses of a cold- and menthol-sensitive cell (C1) compared to a cold-insensitive, menthol-insensitive DU145 cell (C2).
D–F. Response to cold is diminished by TRPM8 knockdown in DU145 cells. Pseudocolor ratiometric [Ca2+]i images in cells transfected with control
siRNA (D) or with TRPM8.4 siRNA (E) at 37uC (upper panels) or 18uC (lower panels). Individual [Ca2+]i responses are represented to the right of the
corresponding images. The amplitude and fraction of cells that respond to cold stimuli is clearly diminished in TRPM8 siRNA-treated cultures. This
effect is quantitatively depicted in F.
doi:10.1371/journal.pone.0051825.g002
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G2/M phases in all tumor cell lines, while 10 mM thio-BCTC was
less potent and DD01050 was most effective on PC3 cells. We also
tested the effect of AMTB and JNJ41876666, novel and highly
specific TRPM8 inhibitors [37,44], on all cell lines. At 10 mM,
both drugs reduced the proliferative fraction of cancer cell lines
while leaving PNT1A cells unaffected. We did not observe any
cytotoxic effects of the drugs at the concentrations used (not
shown). Collectively, the results obtained with the different
blockers are consistent with the view that inhibition of TRPM8
results in a reduced proliferation in prostatic cancer cells.
Knock Down of TRPM8 Message Reduces Prostate Cancer
Cell Proliferation
To achieve a more direct correlation between TRPM8
expression and tumor cell proliferation, we used siRNA against
TRPM8 and measured its effects on proliferation and cell cycle
distribution in the three tumor prostatic cell lines and the non-
tumoral one. As a positive control we used siRNA directed against
hGAPDH. As GAPDH is a key enzyme of glycolysis, reduction of
the protein is reflected on the metabolic activity of transfected
cells. This was demonstrated for the four cell lines by MTT assays
(not shown) and flow cytometry (Fig. 5A).
The use of multiple functional siRNAs is advised to ensure the
specificity of the phenotypic effects observed because sequences
targeting different parts of the message should have qualitatively
the same effects. Quantitatively, different siRNAs targeting the
same gene are often not equally effective because of thermody-
namic properties, stability, and positioning of either the siRNAs
themselves or of the target region of the gene. We therefore tested
four different siRNAs directed against TRPM8, which have been
designated TRPM8.1–4. These siRNAs recognize distinct target
sequences in TRPM8 and differ in their silencing potency in the
different cell lines. To reduce the possibility of off-target effects, we
used a low concentration of siRNA (25 nM) and optimized the
Figure 3. TRPM8 channel blockers reduce proliferation in prostate cancer cells. Growth of the indicated cell lines in the presence of TRPM8
inhibitors. MTT hydrolysis, expressed as fold increase, has been normalized to levels at time 0. Clotrimazole (solid squares), BCTC (solid circles), thio-
BCTC (open squares) and DD01050 (triangles) over 5 days of experiment. Data points represent average of 4 experiments 6 SEM. *: p,0.05; **:
p,0.01; ***: p,0.005. The blockers were used in a final concentration of 10 mM.
doi:10.1371/journal.pone.0051825.g003
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transfection time. For this, we incubated each cell type with
equilibrated siRNA-transfection reagent mix for 4, 6, 8, 12, and
24 h, and monitored 24 and 48 hours afterwards the relative
reduction in TRPM8 elicited by TRPM8.3 and TRPM8.4 using
real time PCR; TRPM8.3 and TRPM8.4 were effective at the
RNA level in all four tested cell lines (including PNT1A) after
incubation of 6 hours with siRNA. We also optimized the
incubation time after siRNA transfection by following the
abundance of TRPM8 mRNA at 12, 24, 72 and 120 hours. For
PNT1A, LNCaP and PC3 the maximum reduction of TRPM8
message using TRPM8.4 siRNA was observed at 72 hours, while
DU145 showed the maximum effect already at 48 hours (Fig. 5B).
Silencing of TRPM8 induced a decrease in proliferation as
measured by MTT assays in the PC3 cell line. MTT hydrolysis in
PNT1A, DU145 and LNCaP cells was not obviously affected by
siRNA (not shown). This is probably a reflection of the different
optimal times for RNA knockdown, because one should expect a
shift by several hours between the reduction in TRPM8 message
and effects on proliferation, which will depend on the doubling
time and the time needed for protein knockdown both of which
are different for each cell type. The reduction of mRNA correlated
with a clear reduction of protein by approximately 50% in all cell
lines at 48 hours (Figure 5C), but the incomplete knockdown could
explain the lack of effects on MTT hydrolysis.
For this reason, we performed measurements of proliferative
fraction, which turned more sensitive. We detected a decrease in
the fraction of cells in S/G2/M phases of the cell cycle in all tumor
cell lines but observed no effect on non-tumor PNT1A cells. An
example of cell cycle distribution measurements in DU145 cells is
shown in Fig. 6A. A decrease in S and G2/M cells is clearly seen
after siRNA treatment. The outcome of the two effective siRNAs
was different depending on the cell lines; PC3 and LNCaP
responded only to one of the two sequences (TRPM8.4, Fig. 6B)
while for DU145 both sequences were effective.
The effects observed under siRNA made it possible to test
whether the inhibition of proliferation induced by pharmacolog-
ical agents is mediated solely by their effects on TRPM8. To test
this, we assessed whether BCTC was able to reduce the growth of
DU145 cells after siRNA treatment. If all effects of BCTC were
mediated through TRPM8, the drug should have less effect on
proliferation after TRPM8 knockdown by siRNA. However,
BCTC (10 mM) inhibited the growth of this cell line to a similar
extent after TRPM8 knockdown, indicating that the effect of
Figure 4. Pharmacological TRPM8 block affects the cell cycle of prostate cancer cells. Histograms show changes in the proliferative
fraction in the presence of channel blockers as determined by flow cytometry cell cycle analysis. All drugs were used at a concentration of 10 mM. The
proliferative fraction under control conditions (vehicle-treated cells) has been considered as 100% of proliferation.
doi:10.1371/journal.pone.0051825.g004
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BCTC on prostate cancer cell proliferation is not entirely due to
TRPM8 inhibition (Fig. 6C).
Previous reports had shown that the viability of LNCaP cells is
reduced by inhibition of TRPM8 [19]. We could confirm this
observation, but LNCaP was the only cell line that showed this
behavior. The viability for PNT1A1 was also decreased after
siRNA transfection, but this effect did not depend on TRPM8,
because it occurred in this cell line also for control siRNAs (data
not shown).
Menthol and Icilin Effects in Proliferation and Viability of
Prostate Cells
Our results confirm the notion that TRPM8 inhibition reduces
cell proliferation of prostate cancer cells. Thus, we decided to test
whether activation of TRPM8 with menthol produced an opposite
effect, that is, an increase in proliferation. Menthol (120 or
300 mM) or icilin (10 mM) were added to the growth medium.
Somewhat paradoxically, menthol has been described to reduce
the viability of LNCaP cells [19]. The original interpretation of
this phenomenon was that the activation of TRPM8 leads to a
sustained Ca2+ influx that induces apoptosis, but menthol might
have off-target effects in these cells as well [22,45]. We did not
observe a systematic reduction in LNCaP cell viability in the
presence of menthol, although there was some increased mortality
in some experiments. Menthol did not alter the viability of other
cell lines (not shown). MTT and flow cytometry experiments in the
four cell lines provided intriguing results.We did not detect any
significant increase induced by menthol or icilin under normal
serum concentration (Fig. 7A). However, in the presence of
Figure 5. Optimization of siRNA treatment in the tested cell lines. A. The effect of GAPDH knockdown on the proliferative fraction of each
cell line was determined. As expected, GAPDH knockdown inhibits proliferation in all cell types. B. Time course of reduction in TRPM8 RNA content by
the indicated TRPM8 siRNA treatment. TRPM8 message was determined at the indicated times after transfection. Relative abundance is referred to
the amount of mRNA at time 0 and corrected for the expression of transferrin receptor as control. C. TRPM8 protein knockdown by TRPM8.3 and
TRPM8.4 siRNA 48 h after transfection. Actin was used as loading control, and the densitometric quantification relative to control siRNA is presented
on the right bar diagram.
doi:10.1371/journal.pone.0051825.g005
Figure 6. siRNA reduces the proliferative fraction of prostatic cancer cells. A. Representative cell cycle histogram of DU145 cells transfected
with control (top) or hTRPM8 siRNA (bottom). The proliferative fraction (S/G2/M) is clearly reduced after TRPM8 knockdown. B. Proliferative fraction
(%) of cells transfected with control or anti TRPM8 siRNA (sequences 3 and 4). The bars represent average of 3–5 experiments. C. BCTC maintains its
inhibitory effects after silencing of TRPM8. Normalized growth of DU145 cells in the presence of 10 mM BCTC, after transfection of the cells with
control (white column) or TRPM8.4 siRNA (black column). Growth in the absence of BCTC represents 100%.
doi:10.1371/journal.pone.0051825.g006
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reduced serum, only DU145 cells showed a modest yet significant
increase in proliferation induced by menthol (Fig. 7B).
Effect of TRPM8 Block on Wound Healing
Recent evidence indicates that TRPM8 activity is a relevant
factor controlling migration of prostate cancer cells [24,46]. We
therefore decided to use a wound-healing assay, a classic method
relaying on the combined effects of proliferation and migration
[47], to study the actions of TRPM8 blockers on disrupted
monolayers of LNCaP, PC3, DU145 and PNT1A cells. In the
presence of normal serum concentration, all cell lines efficiently
reduced the wound area; the tumor cell lines required shorter
times to close the wound compared to the non-tumoral lines
(Fig. 8A left, C). Wound healing was significantly inhibited by the
specific TRPM8 blockers AMTB and JNJ41876666, in PC3,
LNCaP and DU145 cells, but not in PNT1A (Figure 8A, C). To
minimize the effects of proliferation, we performed the same
analysis in all cell lines at 12 h; JNJ41876666 reduced wound
healing in all tumor cell lines, but not in PNT1A cells (Fig. 8B).
In low serum concentrations, PNT1A cells failed to close the
wound in 48 hours while all three cancer cell lines reduced
significantly the wound surface within 24 h; under such condi-
tions, JNJ41876666 significantly delayed wound healing in all
cancer cell lines, while not in PNT1A (Figure 8D); AMTB
produced essentially the same effects (data not shown). These
results reinforce the idea that the effects of TRPM8 are context-
dependent, and that the channel is required for wound healing in
the cancer cell lines and not in the normal prostate epithelial line.
We also performed scratch assays in the presence of TRPM8
activators, menthol and icilin. We observed only a modest
(although significant) increase in wound healing induced by
menthol in DU145 cells, while LNCaP, PC3 and PNT1A cells
showed no effect (Fig. 8D). Again, these results indicate that
although TRPM8 is important to sustain proliferation and
migration of prostate cancer cells (but not of normal epithelium),
it is not the only determinant of this process.
Discussion
TRPM8 channels have been attributed a role in the generation
and progression of prostate cancer. They were initially thought to
be expressed in prostate cancer and in non-prostatic tumors
(breast, colon, lung and skin) while its expression in the normal
tissue was apparently almost undetectable [8], although this
concept has been challenged by many other reports (e.g. [21]) and
the results described here. A growing body of evidence supports
the idea that the expression of TRPM8 in prostate cancer can be
used as a prognostic marker and a tool for the design of novel
cancer therapies [8,19,21,25,48,49]. Furthermore, TRPM8 has
even been proposed as a potential target for tumor immunother-
apy [50–52]. Despite the growing literature regarding the
physiological role of TRPM8, its role in the oncogenesis of
prostate cancer remains poorly understood.
Our data are consistent with the notion that TRPM8 plays a
relevant role in prostate cancer progression. Furthermore, we
detected limited quantitative differences in TRPM8 expression
between the tumor cell lines tested (DU145,LNCaP.PC3),
despite their radically different behavior in terms of aggressiveness,
proliferation rates and differentiation. DU145, LNCaP and PC3
cells expressed both TRPM8 mRNA and protein. Furthermore, all
tested cells, except PNT1A, showed a Ca2+ increase in response to
cold that could be blocked by TRPM8 blockers [38]. The
differences between our study and data of other laboratories could
be due to the technique used (PCR against real-time PCR) because
the PNT1A is derived from normal epithelial cells and it has been
shown that there is a moderate mRNA expression in this tissue
[8,53].
At first view, the fact that TRPM8 expression is not exclusive of
prostate cancer cells might be regarded as a drawback for the
design of therapies based on TRPM8 inhibition. However, our
pharmacological blockade and siRNA experiments strongly
support the idea that the inhibition of the channel reduces the
proliferation of cancer cells without affecting non-tumor cell
proliferation, despite the fact that non-tumor cells also express
Figure 7. Menthol increases metabolic activity of DU145 cells but does not influence cell cycle distribution. A. The effect of menthol
(two different concentrations) and icilin (10 mM) on the proliferative fraction of each cell line was determined. No effect was detected. Data are
presented normalized to the proliferative fraction in the absence of TRPM8 activators. B. In serum-deprived cells, moderate concentrations of
menthol elicited an increase in metabolic activity of DU145 cells measured by MTT assay. The effect was weaker at higher concentrations.
doi:10.1371/journal.pone.0051825.g007
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TRPM8. In other words, TRPM8 appears to be required only for
tumor cell proliferation and not for normal proliferation.
Interestingly, DU145 cells, which serve as a model for aggressive
androgen-independent prostate cancer, were the most sensitive cell
type to proliferation inhibition by TRPM8 block. This cell line was
also the only one were we observed indications that activation of
the channel can enhance proliferation.
The siRNA treatment produced different effects on proliferation
depending on whether the measurement was performed using
MTT of by direct determination of the proliferative fraction.
siRNA unequivocally reduced the proliferative fraction in all
tumor cell lines, while the effects on proliferation measured as
MTT hydrolysis were marginal if at all significant, except for the
case of PC3 cells, which showed a dramatic decrease in MTT
hydrolysis. We think that the time course of knockdown of the
message, which is different for each of the cell lines, is crucial in
this context. In the case of DU145 cells, the RNA level decreases
very fast, but also recovers rapidly. And while PC3 cells show a
steady and early-onset of RNA level reduction, it decreases only
very late in LNCaP cells. This observation highlights the
importance of optimization of knockdown times if indirect assays
such as metabolic activity determinations are to be performed.
Reduction of the message in LNCaP cells required 72 hours,
comparable to their doubling time (about 60 hours). This would
preclude the use of standard growth curves as a measure of the
impact of siRNA treatment on proliferation. Measurement of the
proliferative fraction of cells seems to be a much more reliable
approach.
Additionally, our data shows that the effects of pharmacological
blockers (BCTC) and siRNA are additive, indicating independent
ways of action. This observation is not entirely surprising given the
fact that the drugs have been described as specific in the sense that
they block other channels with different efficiency. In the future, it
would be desirable to repeat these experiments with more specific
blockers of TRPM8 channels.
Our data confirm most of the previously reported observations
in LNCaP cells [18,19]. However, some of the new findings
require alternative explanations to the prevailing view so far. For
example, the described proapoptotic effect of menthol in LNCaP
cells does not appear to correlate with decreased growth or loss of
viability when cell cycle distribution and PI exclusion are
measured. We did not observe changes in cell viability or
proliferative fraction in the presence of up to 300 mM menthol
or 10 mM icilin in any cell line. In as much as menthol increased
[Ca2+] in PC3 and DU145 cells similarly to LNCaP, it is unlikely
that a sustained Ca2+ influx is responsible for the toxic effect
described for LNCaP cells. The modest effects observed could be a
reflection of the low percentage of cells responding to chemical
stimuli [38]. DU145 shows even increased proliferation in the
presence of menthol under low serum. This effect did not occur in
Figure 8. TRPM8 inhibition impairs migration of prostate tumor cells. Wound healing assays were performed on PNT1A, LNCaP, PC3 and
DU145 cells in the absence or the presence of the TRPM8 inhibitors AMTB and JNJ41876666 (10 mM). A. Representative images of experiments
performed in the presence of normal serum concentrations. In the absence of blocker, all cell lines efficiently restore the monolayer after 24 (LNCaP
and DU145) or 48 h (PNT1A; at 24 h, no recovery was observed). The presence of blockers impairs healing in LNCaP, PC3 and DU145, but not in
PNT1A cells. B. Similar effects were observed on all cell lines already 12 h after the scratch. C. Quantification of restored surface from three images like
those in A, for 24 h in all cell lines, except PNT1A (48 h) in the presence of JNJ41876666 (black) and AMTB (red). D. Similar experiments in low serum
concentrations revealed that PNT1A did not reduce the scratch surface, while cancer cells LNCaP and PC3 (in 3% FCS) and DU145 (in 1% FCS) did.
Healing was again inhibited by JNJ41876666 (10 mM). E. Menthol induced a slight acceleration of healing only in DU145 cells, while icilin showed no
effect on any of the lines tested.
doi:10.1371/journal.pone.0051825.g008
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the presence of normal serum concentration, indicating that
TRPM8 expression does not represent an advantage for growth
under optimal conditions, but does improve it under limited
growth factor supply. Since DU145 cells do not express androgen
receptor, and the expression of TRPM8 in other cell lines has been
reported to be enhanced by androgens [18] it is reasonable to
speculate that DU145 is the only cell line that shows stimulated
growth in the presence of menthol because it has enough
expression of the channel in the absence of androgens.
Several of our observations point to a context-dependent role of
TRPM8, which seems necessary for cell cycle progression and
migration of LNCaP and DU145 cancer cells, while it has only
small (if any) effects in non-cancer PNT1A cells and has been
reported to inhibit migration of PC3 cells [24,46]. Although this is
not an unusual observation, since prominent cancer-related factors
such as the TNF-related apoptosis-inducing ligand, (TRAIL e.g.
[54]), retinoids [55] or IL-24 [56] can show a similar behavior, it
highlights the need to carefully select appropriate models when
trying to exploit the therapeutic potential of TRPM8.
In summary, we provide evidence supporting a tumor-specific
role of TRPM8 rather than a tumor-specific expression of the
channel, thus reinforcing the relevance of this channel as a
promising candidate for prostate cancer therapy.
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